Drug intelligence / Profile preview

Compound A2

Development stage: Preclinical
Lead developer: Universidad de Navarra
Modality: Small Molecules

Overview

Compound A2 is a novel selenium-containing derivative of flutamide, a non-steroidal antiandrogen used in the treatment of prostate cancer. Developed as part of a series of Se-flutamide analogs, Compound A2 is designed to enhance antiproliferative activity against both androgen receptor (AR)-dependent and AR-independent prostate cancer cell lines. In preclinical studies, it has demonstrated potent inhibitory effects on LNCaP (AR-dependent), DU-145, and PC-3 (AR-independent) cells. Its mechanism of action involves the antagonism of the androgen receptor and the potential induction of regulated cell death pathways, such as apoptosis and cell cycle arrest, offering a broader therapeutic potential than conventional flutamide.

Other names: Se-flutamide derivative a2

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Compound A2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound A2.

Explore the full profile